论文部分内容阅读
目的探讨尤瑞克林联合巴曲酶治疗急性大脑中动脉脑梗死的近期疗效和安全性。方法选择急性大脑中动脉脑梗死患者92例,随机分为联合治疗组(尤瑞克林+巴曲酶)32例、巴曲酶组31例、和对照组(常规治疗组)29例。观察3组治疗前后NIHSS评分(美国国立卫生院卒中量表)的变化。结果 3组治疗前NIHSS评分无差异,在治疗后14、28dNIHSS评分显示:联合治疗组神经功能明显改善,巴曲酶组有所改善,对照组恢复最差,3组间比较有统计学差异。所有病例无严重不良反应发生。结论尤瑞克林联合巴曲酶治疗急性大脑中动脉脑梗死安全、有效。
Objective To investigate the efficacy and safety of uracil combined with batroxobin in the treatment of acute middle cerebral artery infarction. Methods Ninety-two patients with acute cerebral infarction of middle cerebral artery were randomly divided into three groups: 32 in combination therapy group (noreclin + batroxobin), 31 in batroxobin group and 29 in control group (conventional treatment group). The changes of NIHSS score (National Institutes of Health Stroke Scale) before and after treatment in 3 groups were observed. Results There was no difference in NIHSS score between the three groups before treatment. On the 14th and 28th day after treatment, the NIHSS scores showed that the neurological function was significantly improved in the combined treatment group, that in the batroxobin group was the best, and that in the control group was the worst. The differences among the three groups were statistically significant. No serious adverse reactions occurred in all cases. Conclusion The combination of uracil and batroxobin in the treatment of acute middle cerebral artery infarction is safe and effective.